Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity

Boulch, Morgane; Cazaux, Marine; Cuffel, Alexis; Guerin, Marion V.; Garcia, Zacarias; Alonso, Ruby; Lemaître, Fabrice; Beer, Alexander; Corre, Béatrice; Menger, Laurie; Grandjean, Capucine L.; Morin, Florence; Thieblemont, Catherine; Caillat-Zucman, Sophie; Bousso, Philippe

doi:10.1038/s43018-023-00570-7

Download PDF

Article
Open access
Published: 29 May 2023

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4⁺ CAR T-cell antitumor activity

Morgane Boulch¹,
Marine Cazaux¹,
Alexis Cuffel ORCID: orcid.org/0000-0003-4036-8558^2,3,
Marion V. Guerin¹,
Zacarias Garcia¹,
Ruby Alonso¹,
Fabrice Lemaître¹,
Alexander Beer¹,
Béatrice Corre¹,
Laurie Menger⁴,
Capucine L. Grandjean¹,
Florence Morin²,
Catherine Thieblemont ORCID: orcid.org/0000-0002-9941-2448⁵,
Sophie Caillat-Zucman^2,3 &
…
Philippe Bousso ORCID: orcid.org/0000-0002-6362-561X¹

Nature Cancer volume 4, pages 968–983 (2023)Cite this article

17k Accesses
24 Citations
130 Altmetric
Metrics details

Subjects

Abstract

CD4⁺ T cells and CD4⁺ chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4⁺ T cells promote tumor regression are incompletely understood. With the help of functional intravital imaging, we report that interferon (IFN)-γ production but not perforin-mediated cytotoxicity was the dominant mechanism for tumor elimination by anti-CD19 CD4⁺ CAR T cells. Mechanistically, mouse or human CD4⁺ CAR T-cell-derived IFN-γ diffused extensively to act on tumor cells at distance selectively killing tumors sensitive to cytokine-induced apoptosis, including antigen-negative variants. In anti-CD19 CAR T-cell-treated patients exhibiting elevated CAR CD4:CD8 ratios, strong induction of serum IFN-γ was associated with increased survival. We propose that the sensitivity of tumor cells to the pro-apoptotic activity of IFN-γ is a major determinant of CD4⁺ CAR T-cell efficacy and may be considered to guide the use of CD4⁺ T cells during immunotherapy.

PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells

Article Open access 24 April 2024

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function

Article Open access 24 April 2024

FOXO1 is a master regulator of memory programming in CAR T cells

Article Open access 10 April 2024

Main

While most tumor immunotherapies aimed at harnessing the killing activity of CD8⁺ T cells, there is increasing evidence that CD4⁺ T cells also play a major role during antitumor immune response both in preclinical models and in patients with cancer^{1,2,3,4,5,6,7,8,9}.

CAR T cells, an effective therapy for B-cell malignancies and an attractive strategy under investigation for other cancers, typically uses a mixture of CD4⁺ and CD8⁺ T cells^{10,11,12,13,14}. We and others have found that these subsets display shared and unique features^15,16. Notably, CD4⁺ CAR T cells can exert potent antitumor activity (and even outperform CD8⁺ CAR T cells) in certain preclinical tumor models^{9,17,18,19,20,21}. By contrast, in other settings, CD4⁺ CAR T cells show no or lower efficacy as compared to CD8⁺ CAR T cells^{15,16,22,23,24,25}. Whether tumor-intrinsic parameters dictate the capacity of CD4⁺ CAR T cells to elicit tumor regression is unclear. More generally, how CD4⁺ CAR T cells eliminate tumor cells in responsive models has yet to be fully understood. Multiple mechanisms have been proposed to explain the antitumor activity of CD4⁺ T cells². Although considered a hallmark of CD8⁺ T cells, CD4⁺ T cells and CD4⁺ CAR T cells can use the granzyme/perforin pathway to mediate target cell lysis^{8,26,27,28,29,30,31,32}. This is likely facilitated in CD4⁺ CAR T cells that do not require major histocompatibility complex (MHC) class II expression on tumor cells for contact-dependent cytotoxic activity (as compared to conventional CD4⁺ T cells). Furthermore, the production of cytokines such as IFN-γ and tumor necrosis factor (TNF)-α by CD4⁺ T cells can induce tumor cell death³³ or senescence³⁴. The same cytokines could also act on the tumor vasculature to promote tumor regression^35,36. CD4⁺ T cells have also the ability to promote macrophage tumoricidal activity^37,38, to favor humoral responses³⁹ or provide help to CD8⁺ T-cell responses^40,41. We have recently shown that CAR T-cell-derived IFN-γ through a crosstalk with the host and the subsequent production of interleukin (IL)-12 promoted the activation of host cytotoxic effectors (CD8⁺ T cells and natural killer (NK) cells) and was also critical to sustain CD8⁺ CAR T-cell killing rate¹⁵; however, how these distinct mechanisms contribute to CD4⁺ CAR T-cell antitumor activity remain to be precisely quantified. More generally, we lack direct evidence of how conventional CD4⁺ T cells or CD4⁺ CAR T cells eliminate tumors.

Here, we report distinct therapeutical benefit for anti-CD19 CD4⁺ CAR T-cell therapy in two models of B-cell malignancy. Using intravital imaging of the bone marrow to quantify killing events in the sensitive tumor model, we established that perforin-dependent killing account for less than a third of tumor cell death during CD4⁺ CAR T-cell therapy. The majority of tumor cell death occurred at a distance from CAR T cells and was strictly dependent on CAR T-cell-derived IFN-γ. We provide evidence that IFN-γ acted directly on tumor cells to promote apoptosis and that tumor sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4⁺ CAR T-cell efficacy.

Results

CD4⁺ CAR T cells exhibit tumor-dependent antitumor activity

The ability of CD4⁺ CAR T cells (CAR4 T cells) to induce tumor regression has been shown to be highly variable in distinct preclinical models of B-cell malignancies or solid tumors. In particular, we have previously shown that CD4⁺ CAR T cells are poorly effective in a model of Myc-driven B-cell lymphoma (Eμ-myc), whereas CD8⁺ CAR T cells (CAR8 T cells) readily induced tumor regression^15,42. To test an additional model of B-cell malignancy, we used Abelson-driven pro-B-cell tumors⁴³ (a model of B-cell acute lymphoblastic leukemia) in the same settings of anti-CD19 CAR4 T-cell therapy in vivo (Fig. 1a and Extended Data Fig. 1a). In mice with established pro-B-cell tumors, CAR4 T cells substantially reduced tumor burden in the bone marrow and blood (Fig. 1b,c and Extended Data Fig. 2a). As expected, CAR4 T cells were incapable of controlling tumor growth in mice bearing Eμ-myc tumors. Consistently, CAR4 T cells increased mouse survival in the pro-B-cell model but did not confer any survival advantage in the Eμ-myc model (Fig. 1d). Of note, levels of CD19 expression or of the adhesion molecule ICAM-1 (typically involved in effector–target contact stabilization) could not account for the differential antitumor responses seen in these two models (Fig. 1e) as values were similar at steady state. Next, we thought to assess whether CAR4 T-cell-mediated tumor control was associated with a higher frequency of tumor cell death. To this end, we relied on intravital imaging of the bone marrow and flow cytometry using Eμ-myc or pro-B-cell tumors expressing a FRET-based caspase 3 reporter. Caspase 3 activity was detected in CAR4 T-cell-treated mice harboring pro-B-cell tumors but was minimal in treated mice with Eμ-myc tumors or in untreated animals (Fig. 1f,g). Together, these experiments prompted us to explore in more detail the mechanisms dictating the antitumor activity of CAR4 T cells against B-cell tumors.

**Fig. 1: Distinct B-cell tumors exhibit differential sensitivities to CAR4 T-cell therapy.**

CAR4 T cells rely on IFN-γ to control pro-B-cell tumors

Given the importance of IFN-γ in antitumor responses, we asked whether the capacity of CAR4 T cells to produce IFN-γ was essential for the control of pro-B-cell tumors. Mice with established tumors were therefore treated with CAR4 T cells that were either competent or deficient for IFN-γ. As shown in Fig. 2a,b, the capacity of CAR4 T cells to control tumor burden in the bone marrow and in the blood was largely reduced when IFN-γ^−/− CAR4 T cells were used for treatment. In addition, while wild-type (WT) CAR4 T cells promoted durable tumor control in approximately half of the animals, IFN-γ^−/− CAR4 T cells provided little if any survival benefit (Fig. 2c). Of note, WT and IFN-γ^−/− CAR4 T cells expressed similar levels of CAR, activation and exhaustion markers at their surface ex vivo (Extended Data Fig. 1b–f). Using intravital imaging, we observed that IFN-γ^−/− CAR4 T cells induced lower levels of caspase 3 activity in tumor cells compared to WT CAR4 T-cell-treated mice (Fig. 2d–g). These differences were not accounted for by a distinct accumulation at the tumor site as IFN-γ^−/− CAR4 T cells accumulated to a slightly higher degree than WT CAR4 T cells (Fig. 2f). Of note, apoptosis events were largely due to the presence of CAR4 T cells as caspase 3 activity was barely detectable in untreated animals (Fig. 2d,e). In sum, our results established that CAR4 T-cell-derived IFN-γ was important for inducing tumor cell death and promoting control of pro-B-cell tumors.

Elimination of tumors by CAR4 T cells without cell contact

To gain additional insight into how CAR4 T cells contribute to tumor destruction, we performed intravital imaging of the bone marrow in mice with established pro-B-cell tumors and treated with WT or IFN-γ^−/− or perforin-deficient (Prf1^−/−) CAR4 T cells. We used the caspase 3 reporter to identify the occurrence of tumor apoptosis during the imaging period. Tumor killing events were classified as ‘direct’ when happening in the context of a contact with a CAR4 T cell and ‘indirect’ when tumor cell death occurred in the absence of detectable CAR4 T-cell contact (Fig. 3a, Extended Data Fig. 3 and Supplementary Video 1). In mice treated with WT CAR4 T cells, a third of tumor apoptosis events were associated with a CAR4 T-cell contact (Fig. 3b–c and Supplementary Video 2), suggesting that CAR4 T cells can exhibit some degree of direct cytotoxicity; however, the majority of tumor cell death occurred at distance from CAR4 T cells (Fig. 3b,c and Supplementary Video 2), suggesting a distinct mechanism for tumor elimination. Notably, when using IFN-γ^−/− CAR4 T cells for treatment, most of the indirect killing events were lost (Fig. 3b,c and Supplementary Video 3). Quantitatively, CAR4 T-cell-derived IFN-γ strongly promoted indirect killing on a per CAR4 T-cell basis (Fig. 3d,e). Of note, there was a reduction in direct killing when using IFN-γ^−/− CAR4 T cells, possibly due to the importance of the IFN-γ–IL-12 axis for maintaining CAR T-cell cytotoxic potential¹⁵. Conversely, we assessed the killing mode of Prf1^−/− CAR4 T cells. In these settings, indirect killing events were detected at similar rate as compared to WT CAR4 T cells (Fig. 3b; NS, P = 0.9312) but direct killing events were largely abrogated (Fig. 3b,e and Supplementary Video 4). This observation suggested in particular that killing scored as ‘indirect’ were unlikely contact-dependent killing in which the lethal hit was not visualized. Thus, direct but not indirect killing events were dependent on the perforin/granzyme activity of CAR4 T cells. The lower contribution of the perforin pathway (over the IFN-γ pathway) to tumor killing by CAR4 T cells was also reflected by the fact Prf1^−/− CAR4 T cells displayed similar therapeutic benefit as compared to WT CAR4 T cells (Fig. 3f). The residual direct killing activity seen when using Prf1^−/− CAR4 T cells may possibly be due to Fas-dependent killing (Extended Data Fig. 4a). We also assessed the occurrence of IFN-γ-dependent and Prf1-dependent killing by CAR4 T cells in vitro. As shown in Extended Data Fig. 4b,c, tumor killing was reduced when using IFN-γ^−/− or Prf1^−/− CAR4 T cells, confirming the involvement of both pathways. Of note, the contribution of Prf1-dependent killing tended to be higher in vitro compared to in vivo, possibly because the assay favored close contacts. Consistently, CRISPR/Cas9-mediated removal of IFN-γ-R1 on pro-B-cell tumors also reduced overall killing by CAR4 T cells (Extended Data Fig. 4d–f). In sum, our in vivo results suggest that CAR4 T cells mostly eliminate tumors remotely in an IFN-γ-dependent mechanism and to a lesser extent during direct tumor cell contact in a perforin-dependent manner.

**Fig. 3: CAR4 T cells eliminate B-cell tumors using both IFN-γ-dependent and perforin-dependent mechanisms.**

CAR4 T-cell-derived IFN-γ is sensed by immune and tumor cells

Having shown the importance of IFN-γ for tumor regression, we confirmed the presence of IFN-γ during CAR4 T-cell therapy. To this end, we measured systemic IFN-γ concentration in the serum of mice treated with WT or IFN-γ^−/− CAR4 T cells. As shown in Fig. 4a, IFN-γ concentration substantially increased upon injection of WT CAR4 T cells but not upon treatment with IFN-γ^−/− CAR4 T cells, indicating that CAR4 T cells represent the major source of IFN-γ. Consistently, WT CAR4 T cells but not IFN-γ^−/− CAR4 T cells were perfectly able to control pro-B-cell tumors in IFN-γ^−/− hosts, suggesting that host-derived IFN-γ does not play a major role in CAR4 T-cell therapeutic activity (Extended Data Fig. 4g–j).

**Fig. 4: CAR4 T-cell-derived IFN-γ diffuses extensively in the tumor microenvironment.**

By comparison, IFN-γ concentrations measured upon CAR8 T-cell treatment were >30 fold lower, highlighting the role of CD4⁺ CAR T cells in generating an IFN-γ-rich milieu (Fig. 4a). This observation is also consistent with the fact the CAR8 T cells were able to control pro-B-cell tumors independently of IFN-γ in vitro and in vivo, and relied primarily on the perforin pathway for killing (Extended Data Fig. 4k–m).

To assess the impact of IFN-γ production at the tumor site, we analyzed MHC class I, ICAM-1 and PD-L1 expression, which are classically upregulated by IFNs. CAR4 T-cell therapy resulted in upregulation of all these markers in both tumor and immune cells and this was partly due to CAR4 T-cell-derived IFN-γ (Fig. 4b,c and Extended Data Fig. 5), possibly due to the additional contribution of type I IFNs. To directly test the extent of IFN-γ diffusion in the tumor microenvironment, we introduced a fluorescent reporter for STAT1 activity⁴⁴ in pro-B-cell tumors (Fig. 4d). Using intravital imaging of the bone marrow, we confirmed that injection of recombinant IFN-γ in mice with established tumors resulted in STAT1 translocation in most tumor cells (Fig. 4e,f). We then assessed STAT1 activity in tumor-bearing mice treated with CAR4 T cells or control CD4⁺ T cells (CTRL4) (Fig. 4g). We used IFN-γ^−/− hosts in these experiments to specifically evaluate the diffusion of CAR T-cell-derived IFN-γ. As shown in Fig. 4h,i, transfer of CAR4 but not CTRL4 T cells resulted in STAT1 translocation throughout the tumor. These observations indicate that IFN-γ acts broadly in the tumor microenvironment, most likely due to the efficient diffusion of this cytokine^44,45.

CAR4 T-cell-derived IFN-γ promotes tumor cell apoptosis

As IFN-γ was essential for indirect killing events, we investigated the mechanism underlying tumor killing events observed at distance from CAR4 T cells. Regarding the long-range effects of IFN-γ, we envisioned at least two possibilities. First, we have previously shown that CAR4 T-cell-derived IFN-γ activates endogenous effectors such as T cells or NK cells by acting on host cells¹⁵ and these effectors could potentially contribute to the observed indirect killing events; however, indirect killing events were present at similar rate when CAR4 T cells were used to treat tumors in Prf1^−/− or WT recipients (Fig. 5a–c, Fig. 3c and Supplementary Video 5). This result suggests that perforin-dependent tumor killing by host cytotoxic effectors did not account for the indirect killing events. We also treated tumor-bearing IFN-γ-R1^−/− recipients with CAR4 T cells to test whether sensing of IFN-γ by host cells was important for antitumor activity in this model. CAR4 T cells effectively controlled tumor burden (Fig. 5d) suggesting that IFN-γ activity on host cells is dispensable for the regression of pro-B-cell tumors although a role at later time point to limit relapses cannot be excluded.

**Fig. 5: CAR4 T-cell-derived IFN-γ directly acts on tumor cells to promote tumor apoptosis.**

A second possibility is that CAR4 T-cell-derived IFN-γ directly acts on tumor cells to mediate remote killing events. Consistent with this hypothesis, we found that pro-B-cell tumors underwent apoptosis in the presence of IFN-γ in vitro as measured by caspase 3 reporter and intracellular staining of activated caspase 3 (Fig. 5e–g and Extended Data Fig. 6). Moreover, direct administration of IFN-γ in tumor-bearing mice reduced tumor burden and this phenomenon was also observed in IFN-γ-R1^−/− recipients in which only tumor cells could sense IFN-γ (Fig. 5h). Finally, we specifically tested the role of IFN-γ sensing by tumor cells. To this end, we generated pro-B-cell tumors using IFN-γ-R1^−/− mice and confirmed their lack of response to IFN-γ exposure (Extended Data Fig. 7a,b). IFN-γ-R1^−/− tumors were mixed with fluorescent IFN-γ-R1 competent pro-B cells and co-injected in CD45.1⁺ congenic hosts (Fig. 5i and Extended Data Fig. 2b). CAR4 T cells displayed strong antitumor activity against IFN-γ-R1^+/+ tumors but were ineffective against IFN-γ-R1^−/− tumors (Fig. 5j), indicating that IFN-γ sensing by tumor cells is essential for CAR4 T-cell activity. Altogether, these data strongly suggest that activity of CAR4 T-cell-derived IFN-γ on tumor cells is responsible for the observed indirect killing events.

To confirm that CAR4 T cells could kill target cells at distance through IFN-γ production, we set up a Transwell assay in which CAR4 T cells and pro-B-cell tumors were placed in the upper chamber, while only tumor cells were present in the bottom chamber (Extended Data Fig. 8a). In this setup, we observed killing of the tumor cells in the bottom chamber, which was partly blocked when using IFN-γ^−/− CAR4 T cells (Extended Data Fig. 8b–e). To test whether long-range tumor killing can also be detected with human cells, we generated human anti-CD19 CAR4 T cells and transduced the human CD19 (hCD19) molecule in the human ovarian adenocarcinoma OVCAR3 tumor cell line (Extended Data Fig. 8f). As shown in Extended Data Fig. 8g, human CAR4 T cells effectively killed OVCAR3 tumors in an antigen-dependent manner, a process that was largely dependent on IFN-γ. Moreover, we confirmed using our Transwell assay that tumor killing by human CAR4 T cells can happen at distance in an IFN-γ-dependent manner (Extended Data Fig. 8h–j).

Our observations raised the possibility that CAR4 T-cell-derived IFN-γ may also act on CD19⁻ tumors, possibly limiting antigen-escape variants. We first tested this idea in vitro by mixing CD19⁺ pro-B cells with CD19⁻ pro-B cells (generated by CRISPR/Cas9) (Extended Data Fig. 9a,b). We observed bystander killing of CD19⁻ targets by CAR4 T cells that was reduced upon neutralization of IFN-γ or when using IFN-γ^−/− CAR4 T cells (Extended Data Fig. 9c,d). Indirect killing required the presence of CD19⁺ targets in the culture, most likely to initiate IFN-γ production. Similar observations were made using human CAR4 T cells and a mixture of CD19⁻ and CD19⁺ OVCAR3 tumors (Extended Data Fig. 9e,f). Second, we tested the emergence of CD19⁻ pro-B-cell tumors in vivo after treatment with WT or IFN-γ^−/− CAR4 T cells (Extended Data Fig. 9g). As shown in Extended Data Fig. 9h, we observed a reduced frequency of CD19⁻ pro-B-cell tumors after treatment with WT as compared to IFN-γ^−/− CAR4 T cells. These results revealed a potential role for CAR4 T-cell-derived IFN-γ in limiting the emergence of antigen-negative tumors.

CAR4 T cells selectively eliminate IFN-γ-sensitive tumors

Distinct tumors exhibit variable sensitivity to IFN-γ-induced cell death^44,46,47,48. We therefore asked whether the sensitivity to IFN-γ-induced cell death dictate the antitumor potential of CAR4 T cells. In line with this idea, we found that Eµ-myc B-cell tumors that are insensitive to CAR4 T-cell therapy did not undergo cell death in the presence of IFN-γ^15,44. Differences in IFN-γ sensitivity were also observed in solid tumors (Extended Data Fig. 10a,b). We found that IFN-γ triggers the cell death of B16 melanoma but not MC38 colon carcinoma cells. Consistently, we found a contribution of IFN-γ in CAR4 T-cell-mediated killing in vitro only for B16-CD19 tumors but not for MC38-CD19 tumors (Extended Data Fig. 10c). In vivo, we observed that WT but not IFN-γ^−/− CAR4 T cells controlled the growth of B16-CD19 tumors and increased survival, extending the importance of CAR4 T-cell-derived IFN-γ to a solid tumor model (Extended Data Fig. 10d,e).

As Myc-driven and Abl-driven B-cell tumors likely differ by other factors, we also generated multiple fluorescent pro-B-cell tumors by viral Abl overexpression. Individually generated tumor cell lines are expected to harbor different genomic alterations and mutations⁴⁹. Investigating seven different pro-B-cell lines, we found that all responded to IFN-γ exposure by upregulating MHC class I molecules and PD-L1 but only five showed substantial cell death (referred to as sensitive cell lines). We selected three sensitive (expressing green fluorescent protein (GFP), yellow fluorescent protein (YFP) or mTom) and one resistant (expressing cyan fluorescent protein (CFP)) cell lines (Fig. 6a,b) that were differently labeled with fluorescent proteins and mixed at equivalent proportion (Fig. 6c). Mice receiving this mixture were treated with WT or IFN-γ^−/− CAR4 T cells or left untreated. All four cell lines were detected in untreated mice although at different frequencies (Fig. 6d and Extended Data Fig. 2c), possibly due to small differences in growth rates. As shown in Fig. 6e, the contribution of each color-coded cell line (normalized to the percentage seen in untreated recipients) was modified by CAR4 T-cell treatment. All three sensitive tumor cell lines were efficiently controlled by CAR4 T cells in a manner that was largely dependent on CAR4 T-cell-derived IFN-γ. Notably, IFN-γ-resistant B-cell tumors were over-represented after CAR4 T-cell therapy (Fig. 6e). We tested whether IFN-γ-R levels may influence tumor sensitivity to IFN-γ-induced cell death. While Eμ-myc cells expressed lower IFN-γ-R levels than pro-B-cell tumors (Extended Data Fig. 7c), both responded to similar concentration of IFN-γ for PD-L1 upregulation (Extended Data Fig. 7d). In addition, there was no obvious correlation between IFN-γ-R levels and sensitivity to IFN-γ-induced cell death in the various Abl-driven pro-B-cell lines generated (Extended Data Fig. 7e and Fig. 6a), suggesting the contribution of other factors to the tumor responses to IFN-γ. In sum, these experiments therefore suggest that CAR4 T cells selectively eliminate tumor cells sensitive to IFN-γ-induced cell death but spare IFN-γ-resistant tumors.

**Fig. 6: CAR4 T cells selectively eliminate IFN-γ-sensitive tumor cells.**

IFN-γ predicts survival in patients with high CAR4 T cells

Our mouse data suggested that IFN-γ production is particularly important for optimal CAR4 T-cell antitumor activity. To test the relevance of these findings in humans, we analyzed a cohort of 63 anti-CD19 CAR T-cell-treated patients with diffuse large B-cell lymphoma (DLBCL), monitoring both CAR4:CAR8 T-cell ratio in the blood and serum concentration of IFN-γ 1 week post-transfer (around the peak of CAR T-cell expansion). As previously reported, we noted extensive differences in CAR4:CAR8 T-cell ratios among patients (Fig. 7a). Notably, we observed that patients with high (above the median) CAR4:CAR8 T-cell ratios exhibited stronger induction of IFN-γ (Fig. 7b). This observation is reminiscent of the higher levels of circulating IFN-γ seen in our mouse model treated with CAR4 T cells compared to CAR8 T cells (Fig. 4a). Most notably, we analyzed the progression-free survival (PFS) and overall survival (OS) of CAR T-cell-treated patients depending on their CAR4:CAR8 ratio and IFN-γ induction after CAR T-cell transfer. In patients with high CAR4:CAR8 ratios, high IFN-γ induction (above the median) was associated with significantly improved PFS and OS (Fig. 7c). By contrast, IFN-γ induction was not predictive of treatment outcome in patients with low CAR4:CAR8 ratios (Fig. 7c). These clinical data support the idea that IFN-γ is a hallmark of potent antitumor activity mediated by the CD4⁺ subset of CAR T cells.

**Fig. 7: High IFN-γ induction is associated with improved survival in patients with DLBCL exhibiting high CAR4:CAR8 T-cell ratios.**

Discussion

CD4⁺ T cells have been shown to exert potent antitumor activity in preclinical and clinical settings^{1,2,3,4,5,6,7,8,9} but we lack direct evidence of how this activity is achieved. Here, we addressed the mechanisms underlying the antitumor activities of CAR4 T cells. We found that when used alone CAR4 T cells can be highly effective at mediating tumor regression in some models but not others. Mechanistically, CAR4 T cells eliminated sensitive tumor cells at distance by forming large IFN-γ fields in the tumor microenvironment. Our results support the idea that the intrinsic sensitivity of tumor cells to the pro-apoptotic effects of IFN-γ is a major determinant of CAR4 T-cell therapy.

CAR4 T cells can exert antitumor activity through multiple mechanisms but the exact contribution of these mechanisms to tumor cell elimination in vivo has remained technically challenging to quantify. The ability to probe tumor apoptosis in real-time using intravital imaging provided us with a unique means to quantify killing events and their dependence on cell contact with CAR4 T cells. Notably, CAR4 T-cell killing through cell–cell interaction accounted for less than a third of total tumor apoptotic events and this killing mode was largely dependent on perforin. Most indirect killing events were independent on perforin but dependent on the capacity of CAR4 T cells to produce IFN-γ and trigger tumor apoptosis at distance. Consistently, this killing mode was essential for the therapeutic benefit of CAR4 T cells in this model.

Recent studies that used a mixture of CAR4 and CAR8 T cells have observed that IFN-γ is dispensable for killing of hematologic tumors^50,51. This finding is not incompatible with our observation as the requirement for IFN-γ described in our study pertains specifically to CAR4 T cells (but not CAR8 T cells). It has been recently shown that IFN-γ can increase contact-dependent killing of CAR T cells by upregulating adhesion molecules on tumor cells such as ICAM-1 (refs. ^51,52) or by sustaining CAR T-cell cytotoxic functions¹⁵. We described here a distinct mechanism whereby IFN-γ produced by CAR4 T cells acts remotely to induce apoptosis, independently of cell contact and of the perforin pathway.

We and others have observed markedly different outcomes when distinct B-cell tumors were treated with CAR4 T cells^{15,16,17,19,21,23}. We provide evidence that the pro-apoptotic effects of IFN-γ were essential for robust CAR4 T-cell activity. Given that mouse or human tumors display highly variable sensitivities to IFN-γ-mediated cell death^44,46,47,48, our results likely provide an explanation for these discrepancies. In fact, by artificially mixing IFN-γ-sensitive and IFN-γ-resistant tumors, we observed outgrowth of resistant cells upon CAR4 T-cell therapy, possibly reflecting the emergence of tumor cells with mutations in the IFN-γ pathway observed in preclinical models^53,54 or in patients treated by immunotherapy⁵⁵. This is not to mean that CAR4 T cells are useless for tumors insensitive to IFN-γ-induced cell death. In fact, when used in combination with CAR8 T cells, CAR4 T cells could also sustain CAR8 T-cell cytotoxicity through IFN-γ production and crosstalk with the tumor microenvironment as we previously reported¹⁵.

Several factors have been shown to contribute to tumor cell death in response to IFN-γ, including the expression levels of IRF1 (refs. ^46,56), IFN-γ-R^57,58, SLFN11 (ref. ⁴⁷), SOCS1 (ref. ⁵⁹), Fas/Fas ligand⁶⁰, TRAIL⁶¹, iNOS⁶² and the production of reactive oxygen species and reactive nitrogen intermediates⁶³. These factors together with the functional response of tumor cells to IFN-γ may represent interesting biomarkers to identify patients who would most benefit from a CAR4 T-cell-enriched infusion product. Indeed, while most patients treated by anti-CD19 CAR T cells are infused with a mixture of CAR4 and CAR8 T cells at very variable ratios^11,12,14, each subset seems endowed with some unique functional capabilities. We have previously observed that CAR4 T cells are generally more effective than CAR8 T cells at activating host effector cells such as CD8⁺ T cells and NK cells¹⁵ and boosting the host immune response may help counteract the emergence of antigen-negative escape variants. In addition, it has been proposed that CAR4 T cells may be less prone to exhaustion as compared to CAR8 T cells¹⁹. Finally, while both CAR4 and CAR8 T cells can produce IFN-γ, we found the production by CAR4 T cells to be >30 fold higher than that mediated by CAR8 T cells in our model. Notably, we observed that CAR T-cell-treated patients with DLBCL with high CAR4:CAR8 ratios were also more prone to display high levels of IFN-γ after CAR T-cell transfer. Induction of IFN-γ upon CAR T-cell transfer was associated with a better clinical outcome, but selectively for patients displaying high CAR4:CAR8 ratios. These data may suggest that IFN-γ is critical for CAR4 T-cell antitumor activity in humans. Given the importance of IFN-γ diffusion in the tumor microenvironment^44,45, CAR4 T cells should largely contribute to the generation of large cytokine fields in the tumor microenvironment that can act at long-distance to eliminate IFN-γ-sensitive tumor cells, possibly including antigen-loss variants as demonstrated herein.

As exemplified here, understanding how tumor-intrinsic factors influence mechanisms of CD4⁺ T-cell activity represents an important step for leveraging the unique contributions of CD4⁺ and CD8⁺ CAR T cells for personalized medicine.

Methods

Ethics statement

Animal studies were approved by the Safety Committee of Institut Pasteur and in accordance with European and French guidelines (CETEA 2017-0038). The maximal tumor size for animal experiments based on solid tumors was 2,000 mm³ and 500 mm³ for experiments based on liquid tumors. Maximal tumor size was not exceeded. The institutional review-board of Saint-Louis Hospital (BIOCART-CPP 2019-77) approved this study and all patients signed informed consent.

Mice and cell lines

C57BL/6J mice were obtained from Envigo. Ifng^−/−, IfngR1^−/−, Prf1^−/−, ROSA^mT/mG, Ubi-GFP, CFP and CD45.1 mice were bred and crossed in our animal facility under specific-pathogen-free conditions, air renewal (20 times per hour), constant ambient temperature of 22 ± 2 °C and 14:10 h light–dark cycle. All mice used were aged 6–8 weeks old. Male mice were used when using male tumor cell lines. Female mice were used when using female tumor cell lines. The lymphoma B-cell tumor was isolated from a male Eμ-myc mouse, a transgenic mouse line developing spontaneous Burkitt-like lymphomas⁶⁴. Immortalized pro-B cells were obtained by transducing bone marrow cells with a retrovirus encoding viral-Abelson kinase (v-abl)⁶⁵. These cell lines were retrovirally transduced to express a reporter for caspase 3 activity (named Eµ-myc-DEVD or Pro-B-DEVD)⁶⁶, YFP or STAT1–GFP fusion protein. Immortalized pro-B cells expressing tdTomato, CFP or GFP were similarly generated by infecting bone marrow cells of ROSA^mT/mG, CFP and Ubi-GFP mice, respectively. Immortalized pro-B cells deficient for IFN-γ sensing were generated by infecting bone marrow cells of IFN-γ-R1^−/− mice. B16.F10 melanoma (ATCC) and MC38 colon adenocarcinoma (Kerafast) cells were retrovirally transduced to express the murine CD19 protein. OVCAR3 ovarian adenocarcinoma cells (ATCC) were retrovirally transduced to express the human CD19 protein. HEK cells (ATCC) were purchased at ATCC. Mice were examined every day and killed in case of prostration, weakness, tousled hair or nodal tumor mass >1 cm. Cells were cultured in RPMI medium 1640-GlutaMAX or DMEM high glucose GlutaMAX supplemented with 10% heat-inactivated fetal bovine serum, 50 U ml⁻¹ penicillin, 50 μg ml⁻¹ streptomycin, 1 mM sodium pyruvate, 10 mM HEPES and 50 μM 2-mercaptoethanol, and maintained at 37 °C and 5% CO₂. All cell lines were regularly tested for the lack of Mycoplasma contamination using the Venor-GeM Advance Mycoplasma detection kit (Minerva Biolabs).

CAR T-cell generation and adoptive transfer

The retroviral vector encoding anti-CD19 CAR (tCD34.2A.amCD19.CD28IEVζ) has been previously described⁶⁷. In brief, the CAR construct comprises the anti-mouse CD19 single-chain fragment variable domain from the 1D3 rat hybridoma, the transmembrane and intracellular domains of CD28 and the CD3ζ intracellular domain. The vector also encodes a truncated form of the human CD34 molecule used for the identification and isolation of CAR-expressing T cells. CD4⁺ and CD8⁺ T cells were purified from spleens and lymph nodes of WT, Ifng^−/− and Prf1^−/− male mice using either CD4-negative or CD8-negative selection kits (Miltenyi Biotec). T cells were stimulated using plates coated with anti-CD3 monoclonal antibodies in the presence of soluble anti-CD28 monoclonal antibody and 10 ng ml⁻¹ murine IL-12 (I8523; Sigma-Aldrich)⁶⁸. T cells were then subjected to two rounds of spin-infections (performed at 24 and 48 h) using retroviral supernatant and 8 μg ml⁻¹ polybrene (Merck). T cells were cultured for 4 d in the presence of 10 ng ml⁻¹ hIL-2 (202-IL; R&D Systems). For in vivo imaging experiments, CAR T cells were retrovirally transduced to express GFP. For comparable in vitro activation, IFN-γ-deficient T cells and their WT counterparts were supplemented with 100 ng ml⁻¹ of IFN-γ (Peprotech). CAR transduction efficacy was routinely >80%; in cases of lower efficacy, transduced cells were isolated using the hCD34 positive selection kit (Miltenyi Biotec). Tumors were established by injecting 0.5 × 10⁶ Eμ-myc cells or 0.5–0.8 × 10⁶ transformed pro-B cells in mice following a conditioning regimen (4 Gy sublethal irradiation) to promote CAR T-cell engraftment⁶⁹. B-cell tumors developed initially in the bone marrow and became detectable in the blood by day 6–7. At this time, CAR T cells (5–20 × 10⁶ cells) were injected i.v. For the solid tumor model, tumors were established by injecting 0.5 × 10⁶ B16-CD19 cells subcutaneously in the flank of sublethally irradiated (4 Gy) mice. Tumors were allowed to grow for 10 d at which time CAR T cells (10 × 10⁶ cells) were injected intravenously. Starting tumor volumes were normalized between treatment groups. Tumor growth was measured every 2–3 d using a caliper.

Human CD4⁺ CAR T cells were generated from peripheral blood mononuclear cells from healthy donors obtained from Etablissement Français du Sang. All donors gave informed consent. CD4⁺ T cells were isolated using the CD4⁺ T-cell isolation kit (Miltenyi Biotec) and stimulated with Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific) in X-VIVO 15 medium (Lonza) supplemented with 5% human serum (Sigma-Aldrich) and 50 μM 2-mercaptoethanol. Twenty-four hours after activation, CD4⁺ T cells were transduced with lentiviral supernatants corresponding to an anti-CD19(FMC63)-CD8tm-CD28-CD3ζ CAR (rLV.EF1.19(FMC63)-28z, Flash Therapeutics) at a multiplicity of infection of 20. After two additional days, CD3/CD28 beads were magnetically removed and CD4⁺ CAR T cells were used for in vitro assays.

Generation of IFN-γ-R1^−/− pro-B cells

A Pro-B-DEVD cell line lacking IFN-γ-R1 was generated by genome editing of Pro-B-DEVD cell tumors with CRISPR/Cas9 using the Alt-R CRISPR-Cas9 System from Integrated DNA Technologies (IDT) and following manufacturer’s recommendations. The sequence used to target IFN-γ-R1 was ATGTGGAGCATAACCGGAGT. Briefly, CRISPR-Cas9 crRNA and CRISPR-Cas9 tracrRNA were purchased from IDT. To form active guide RNA complexes, an equimolar concentration of crRNA and tracrRNA (1 µM each) were hybridized by heating up to 95 °C for 5 min and allowed to cool slowly to 23 °C in a PCR thermocycler. CRISPR–ribonucleoprotein (RNP) complexes were formed by mixing 1 µg S.p. HiFi Cas9 Nuclease V3 (IDT) to gRNA for 10 min at room temperature. One million pro-B-cell tumors were resuspended in 20 µl of nucleofection solution with 3 µl RNP and transferred to nucleocuvette strips (SF Cell Line 4D-Nucleofector X Kit S, Lonza) for electroporation using the DN-110 program of 4D-Nucleofector X Unit. Electroporated cells were cultured for 3 d at 32 °C in 5% CO₂ to allow genome editing. Effective IFN-γ-R1 ablation was confirmed by flow cytometry.

IFN-γ treatments

For in vitro IFN-γ exposure on tumor cells, different IFN-γ (recombinant murine IFN-γ; Peprotech or recombinant human IFN-γ; Peprotech) concentrations were used ranging from 0.005–1,000 ng ml⁻¹ for the indicated time. For in vivo cytokine supplementation studies, murine IFN-γ (10 μg in 100 μl sterile PBS) was delivered twice i.v. for 2 d starting 7–8 d after tumor inoculation.

Transwell assay

To assess the ability of IFN-γ to diffuse and induce tumor killing at distance, a Transwell assay was set up. Tumor cells and CAR T cells were co-cultured in the upper chamber of a 24-well Transwell plate (0.4-µm pore polycarbonate membrane insert; Corning). Tumor cells were added to the lower chamber. At 24–48 h later, tumor cells from the lower chamber were collected and analyzed using flow cytometry. When indicated, IFN-γ and IFN-γ-R1 were neutralized by adding blocking antibodies in the top and bottom chambers.

Multiplex assay for cytokine quantification

Sera were isolated from blood obtained by cardiac puncture 3 d after CAR T-cell transfer and snap frozen before storage at −20 °C until analysis. Multiplex cytokine assay was performed using 26-Plex ProcartaPlex Panel (Invitrogen). Plates were incubated overnight at 4 °C under agitation and analyses were performed using a Bio-Plex 200 system and the Bio-Plex Manager software (Bio-Rad).

Flow cytometry and antibodies

Bone marrow cells were obtained from tibias and femurs and filtered using 70-µm cell strainers. Spleen cells were filtered through 70-µm cell strainers. After killing the mice, blood was collected by cardiac puncture and treated with a red blood cell lysis buffer (eBiosciences). When indicated, cells were stained with live/dead (Fixable Viability Dye eFluor 780 (eBioscience) or Zombie NIR Fixable Viability kit (BioLegend)) staining during 20 min at room temperature. Then single-cell suspensions were Fc-blocked using anti-CD16/32 monoclonal antibodies and normal murine serum 1%. Staining was performed with the following monoclonal antibodies: hCD34-PE or Alexa Fluor 647, hCD19-APC, hHLA-A,B,C-BV605, hPD-L1-PE, CD4-BUV395 or BV786, CD8a-BUV395, CD11b-BUV395, CD19-PE/Cy7 or APC-fire750, CD44-Alexa488, CD45.1-PE, CD45.2-BUV737, CD62L-BV421, H-2Db-APC, H-2Kb-PE/Cy7, LAG-3-APC-fire750, PD-1-PE/Cy7, PD-L1-APC or BV785, TIGIT-PE and Tim-3-BV785. For surface ICAM-1 and IFN-γ-R1 staining, cells were stained with biotin-conjugated anti-ICAM-1 monoclonal antibody or biotin-conjugated anti-CD119 (IFN-γ-R1) monoclonal antibody, respectively and then PE-conjugated streptavidin or APC-fire750-conjugated streptavidin. Intracellular staining was performed using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s guidelines and Alexa647-conjugated anti-active caspase 3 monoclonal antibody. Analyses were performed using a Cytoflex LX (Beckγman Coulter) flow cytometer, CytExpert 2.3 software (Beckman Coulter) and analyzed with FlowJo v.10.8.1 (BD). Tumor cell apoptosis was quantified using a FRET-based reporter for caspase 3 activity. FRET loss was defined as new parameter using the ratio of CFP to FRET fluorescence. FRET loss was quantified after fixing cells with 2% paraformaldehyde solution (Sigma) directly after ex vivo isolation. Murine IFN-γ was blocked using 50 µg ml⁻¹ of purified anti-mouse IFN-γ antibody. Human IFN-γ and IFN-γ-R1 were blocked using 50 µg ml⁻¹ of purified mouse anti-human IFN-γ and 25 µg ml⁻¹ of anti-human IFN-γ-R1 antibody, respectively. For TRAIL and FasL neutralization, 2 µg ml⁻¹ of anti-mouse CD253 (TRAIL) antibody and 10 µg ml⁻¹ of purified anti-mouse/rat CD178 (FasL) antibody were used, respectively. Further information on antibody clones, dilutions and providers is available in the Nature Research Reporting Summary linked to this article.

In vitro imaging

Plastic dishes were coated with poly-d-lysine (Sigma, 0.01% dilution in PBS) for 30 min at 37 °C. Cells were incubated in the culture dishes in complete RPMI without phenol red containing or not IFN-γ (50 ng ml⁻¹) for the indicated time before being subjected to imaging. In vitro two-photon imaging was performed using an upright microscope (FVMPE-RS, Olympus), a ×25/1.05 numerical aperture, water-dipping objective combined with an objective heater and using FV31S-SW software (Olympus). An Insight DeepSee dual laser (Spectra-Physics) tuned at 880 nm was used for excitation. The following filters were used: CFP (483/32) and YFP (542/27). Timelapse sequences were typically created by scanning a 25-μm-thick tissue volume using 5-μm z-steps and 30-s intervals.

Intravital two-photon imaging of the bone marrow

Bone marrow in vivo imaging was performed 2–3 d after CAR T-cell treatment⁴². During imaging experiments, mice were supplied with oxygen and temperature was kept at 37 °C using a heated pad. Two-photon imaging was performed with an upright microscope (FVMPE-RS, Olympus), a ×25/1.05 NA water-dipping objective equipped with an objective heater and using FV31S-SW software (Olympus). An Insight DeepSee dual laser (Spectra-Physics) tuned at 860 or 880 nm was used for excitation. The following filters were used: CFP (483/32), GFP (520/35 or 512/25), YFP (542/27) and background (593/40). Timelapse sequences were created by scanning a 30–40-μm-thick tissue volume using 5-μm z-steps and 60-s intervals.

Image analysis

Videos were processed and analyzed using Fiji software (ImageJ v.2.3.0). Figures and videos based on two-photon microscopy are two-dimensional maximum intensity projections of three-dimensional data. Tumor apoptotic events were quantified manually and scored as direct killing when a CAR T cell interacted with the tumor cell before the detection of FRET loss or as indirect killing when tumor cells underwent FRET loss without any detectable interactions with a CAR T cell during the imaging period. For determining the area occupied by tumor cells, by apoptotic tumors and by CAR T cells from in vivo images, each fluorescent channel was binarized and the corresponding signals were quantified by Fiji software.

For STAT1 translocation analysis, a coefficient of variation was calculated as the ratio of the s.d. to the mean of the STAT1–GFP signal for each cell. A translocation index was then defined as 1 / coefficient of variation and reflected the homogeneity of STAT1–GFP distribution in individual tumor cells.

Patients and immune monitoring

We studied 63 consecutive patients (mean age 62 years; 22 women and 41 men) with aggressive DLBCL who received commercial axicabtagene ciloleucel (axi-cel, n = 35) or tisagenlecleucel (tisa-cel, n = 28) between April 2019 and September 2020 in Saint-Louis Hospital. One-year estimates of PFS and OS were evaluated based on the Lugano criteria⁷⁰. Parameters of immune monitoring were routinely determined as a standard of care. Peripheral blood expansion of CD4⁺ and CD8⁺ CAR T cells was determined every 2 d during the first month after injection by flow cytometry using CD19 CAR detection reagent (Miltenyi Biotech) as reported⁷¹. Serum IFN-γ levels (Ella, ProteinSimple) were measured at baseline (day 0) and around the peak of CAR T-cell expansion (day 7). The study was performed under institutional review-board-approved protocols and all patients signed informed consent.

Statistics and reproducibility

No statistical method was used to predetermine sample size but our sample sizes are similar to those reported in previous publications. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. No data were excluded from the analyses. For two groups statistical testing, data met the assumptions of the statistical tests used. All statistical tests were performed using Prism v.9.2.0 (GraphPad). Data are expressed as mean ± s.e.m. Unpaired Student’s t-test, Mann–Whitney U-test, one-way ANOVA, two-way ANOVA and log-rank tests were used as indicated in figure legends, using post hoc Tukey and Holm-Sidak test for multiple comparison correction. All statistical tests were two-tailed with a significance level of 0.05. NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Source data have been provided as Source Data files. All other data supporting the findings of the present study are available from the corresponding author on reasonable request. Source data are provided with this paper.

References

Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 28, 5–17 (2021).
CAS PubMed Google Scholar
Poncette, L., Bluhm, J. & Blankenstein, T. The role of CD4 T cells in rejection of solid tumors. Curr. Opin. Immunol. 74, 18–24 (2021).
PubMed Google Scholar
Li, T., Wu, B., Yang, T., Zhang, L. & Jin, K. The outstanding antitumor capacity of CD4(+) T helper lymphocytes. Biochim. Biophys. Acta, Rev. Cancer 1874, 188439 (2020).
CAS PubMed Google Scholar
Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell 177, 556–571 (2019).
CAS PubMed PubMed Central Google Scholar
Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133 (2017).
CAS PubMed PubMed Central Google Scholar
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
CAS PubMed PubMed Central Google Scholar
Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4⁺ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).
CAS PubMed PubMed Central Google Scholar
Cachot, A. et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci. Adv. 7, eabe3348 (2021).
CAS PubMed PubMed Central Google Scholar
Nelson, M. H. et al. Identification of human CD4(+) T cell populations with distinct antitumor activity. Sci. Adv. 6, eaba7443 (2020).
CAS PubMed PubMed Central Google Scholar
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
CAS PubMed PubMed Central Google Scholar
Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
CAS PubMed PubMed Central Google Scholar
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
CAS PubMed PubMed Central Google Scholar
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
PubMed PubMed Central Google Scholar
Awasthi, R. et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 4, 560–572 (2020).
CAS PubMed PubMed Central Google Scholar
Boulch, M. et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci. Immunol. 6, eabd4344 (2021).
CAS PubMed Google Scholar
Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8⁺ and CD4⁺ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492–500 (2016).
CAS PubMed Google Scholar
Cheadle, E. J. et al. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4⁺ and CD8⁺ T cells. J. Immunother. 32, 207–218 (2009).
PubMed Google Scholar
Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).
PubMed PubMed Central Google Scholar
Yang, Y. et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci. Transl. Med. 9, eaag1209 (2017).
PubMed PubMed Central Google Scholar
Wang, D. et al. Glioblastoma-targeted CD4⁺ CAR T cells mediate superior antitumor activity. JCI Insight 3, e99048 (2018).
PubMed PubMed Central Google Scholar
Agarwal, S. et al. In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol. Ther. 28, 1783–1794 (2020).
CAS PubMed PubMed Central Google Scholar
Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
CAS PubMed PubMed Central Google Scholar
Qin, H. et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci. Transl. Med. 11, eaaw9414 (2019).
CAS PubMed PubMed Central Google Scholar
Liadi, I. et al. Individual motile CD4(+) T cells can participate in efficient multikilling through conjugation to multiple tumor cells. Cancer Immunol. Res. 3, 473–482 (2015).
CAS PubMed PubMed Central Google Scholar
Ishii, K. et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J. Clin. Invest. 130, 5425–5443 (2020).
CAS PubMed PubMed Central Google Scholar
Xie, Y. et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651–667 (2010).
CAS PubMed PubMed Central Google Scholar
Quezada, S. A. et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
CAS PubMed PubMed Central Google Scholar
Hombach, A., Kohler, H., Rappl, G. & Abken, H. Human CD4⁺ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J. Immunol. 177, 5668–5675 (2006).
CAS PubMed Google Scholar
Nelles, M. E. et al. Murine splenic CD4(+) T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunol. Res. 2, 1113–1124 (2014).
CAS PubMed Google Scholar
Lu, Y. et al. Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors. Cancer Cell 33, 1048–1060 (2018).
CAS PubMed PubMed Central Google Scholar
Sledzinska, A. et al. Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4(+) T cells. Immunity 52, 151–166 (2020).
CAS PubMed PubMed Central Google Scholar
Bailey, S. R. et al. Human CD26^high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat. Commun. 8, 1961 (2017).
Kotredes, K. P. & Gamero, A. M. Interferons as inducers of apoptosis in malignant cells. J. Interferon Cytokine Res. 33, 162–170 (2013).
CAS PubMed PubMed Central Google Scholar
Braumuller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).
PubMed Google Scholar
Qin, Z. & Blankenstein, T. CD4⁺ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 12, 677–686 (2000).
CAS PubMed Google Scholar
Kammertoens, T. et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature 545, 98–102 (2017).
CAS PubMed PubMed Central Google Scholar
Haabeth, O. A. W. et al. CD4⁺ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages. Blood Adv. 4, 2595–2605 (2020).
CAS PubMed PubMed Central Google Scholar
Bogen, B., Fauskanger, M., Haabeth, O. A. & Tveita, A. CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models. Cancer Immunol. Immunother. 68, 1865–1873 (2019).
CAS PubMed Google Scholar
Gnjatic, S. et al. Survey of naturally occurring CD4⁺ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl Acad. Sci. USA 100, 8862–8867 (2003).
CAS PubMed PubMed Central Google Scholar
Keene, J. A. & Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768–782 (1982).
CAS PubMed PubMed Central Google Scholar
Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).
CAS PubMed Google Scholar
Cazaux, M. et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J. Exp. Med. 216, 1038–1049 (2019).
CAS PubMed PubMed Central Google Scholar
Rosenberg, N., Baltimore, D. & Scher, C. D. In vitro transformation of lymphoid cells by Abelson murine leukemia virus. Proc. Natl Acad. Sci. USA 72, 1932–1936 (1975).
CAS PubMed PubMed Central Google Scholar
Thibaut, R. et al. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Cancer 1, 302–314 (2020).
CAS PubMed PubMed Central Google Scholar
Hoekstra, M. E. et al. Long-distance modulation of bystander tumor cells by CD8(+) T cell-secreted IFN-γ. Nat. Cancer 1, 291–301 (2020).
CAS PubMed PubMed Central Google Scholar
Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163–189 (2004).
CAS PubMed Google Scholar
Mezzadra, R. et al. SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing. PLoS ONE 14, e0212053 (2019).
CAS PubMed PubMed Central Google Scholar
Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016).
CAS PubMed PubMed Central Google Scholar
Unnikrishnan, I., Radfar, A., Jenab-Wolcott, J. & Rosenberg, N. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol. Cell. Biol. 19, 4825–4831 (1999).
CAS PubMed PubMed Central Google Scholar
Bailey, S. R. et al. Blockade or deletion of IFN-γ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 3, 136–153 (2022).
PubMed PubMed Central Google Scholar
Larson, R. C. et al. CAR T cell killing requires the IFN-γR pathway in solid but not liquid tumours. Nature 604, 563–570 (2022).
CAS PubMed Google Scholar
Kantari-Mimoun, C. et al. CAR T-cell entry into tumor islets is a two-step process dependent on IFN-γ and ICAM-1. Cancer Immunol. Res. 9, 1425–1438 (2021).
CAS PubMed Google Scholar
Arenas, E. J. et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat. Commun. 12, 1237 (2021).
CAS PubMed PubMed Central Google Scholar
Williams, J. B. et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells. Nat. Commun. 11, 602 (2020).
CAS PubMed PubMed Central Google Scholar
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
CAS PubMed PubMed Central Google Scholar
Aqbi, H. F., Wallace, M., Sappal, S., Payne, K. K. & Manjili, M. H. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J. Leukoc. Biol. 103, 1219–1223 (2018).
Bernabei, P. et al. Interferon-γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J. Leukoc. Biol. 70, 950–960 (2001).
CAS PubMed Google Scholar
Kmieciak, M., Payne, K. K., Wang, X. Y. & Manjili, M. H. IFN-γ Rα is a key determinant of CD8⁺ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS ONE 8, e82544 (2013).
PubMed PubMed Central Google Scholar
Bullock, B. L. et al. Tumor-intrinsic response to IFN-γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci. Alliance 2, e201900328 (2019).
PubMed PubMed Central Google Scholar
Xu, X., Fu, X. Y., Plate, J. & Chong, A. S. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58, 2832–2837 (1998).
CAS PubMed Google Scholar
Shin, E. C. et al. IFN-γ induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int. J. Cancer 93, 262–268 (2001).
CAS PubMed Google Scholar
Vadrot, N. et al. Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN-γ-induced apoptosis in several human hepatoma cell lines. J. Interferon Cytokine Res. 26, 901–913 (2006).
CAS PubMed Google Scholar
Rakshit, S. et al. Interferon-γ induced cell death: regulation and contributions of nitric oxide, cJun N-terminal kinase, reactive oxygen species and peroxynitrite. Biochim. Biophys. Acta 1843, 2645–2661 (2014).
CAS PubMed Google Scholar
Harris, A. W. et al. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353–371 (1988).
CAS PubMed Google Scholar
Lenden Hasse, H. et al. Generation and CRISPR/Cas9 editing of transformed progenitor B cells as a pseudo-physiological system to study DNA repair gene function in V(D)J recombination. J. Immunol. Methods 451, 71–77 (2017).
CAS PubMed PubMed Central Google Scholar
Breart, B., Lemaitre, F., Celli, S. & Bousso, P. Two-photon imaging of intratumoral CD8 T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118, 1390–1397 (2008).
CAS PubMed PubMed Central Google Scholar
Cheadle, E. J. et al. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J. Immunol. 192, 3654–3665 (2014).
CAS PubMed Google Scholar
Andrijauskaite, K. et al. IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8⁺ T cells. Cancer Gene Ther. 22, 360–367 (2015).
CAS PubMed PubMed Central Google Scholar
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886 (2010).
CAS PubMed PubMed Central Google Scholar
Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059–3068 (2014).
PubMed PubMed Central Google Scholar
Galli, E. et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 55, 2347–2349 (2020).
PubMed Google Scholar

Download references

Acknowledgements

We thank members of the Bousso laboratory for critical review of the paper. We are grateful to F. Sepulveda for providing Prf1^−/− mice. We acknowledge the mouse facility and CB UTechS at Institut Pasteur for support in conducting the present study. The work was supported by Institut Pasteur, INSERM, INCa (PLBIO21-104) and an Advanced grant (ENLIGHTEN) from the European Research Council (P.B.).

Author information

Authors and Affiliations

Institut Pasteur, Université de Paris Cité, INSERM U1223, Dynamics of Immune Responses Unit, Equipe Labellisée Ligue Contre le Cancer, Paris, France
Morgane Boulch, Marine Cazaux, Marion V. Guerin, Zacarias Garcia, Ruby Alonso, Fabrice Lemaître, Alexander Beer, Béatrice Corre, Capucine L. Grandjean & Philippe Bousso
Université de Paris Cité, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d’Immunologie, Paris, France
Alexis Cuffel, Florence Morin & Sophie Caillat-Zucman
INSERM UMR976, Institut de Recherche St-Louis, Paris, France
Alexis Cuffel & Sophie Caillat-Zucman
Gustave Roussy, Villejuif, France; INSERM U1015, Villejuif, France
Laurie Menger
Service d’Hémato-Oncologie, Hôpital Saint-Louis, AP-HP, Université de Paris Cité, Paris, France
Catherine Thieblemont

Authors

Morgane Boulch
View author publications
You can also search for this author in PubMed Google Scholar
Marine Cazaux
View author publications
You can also search for this author in PubMed Google Scholar
Alexis Cuffel
View author publications
You can also search for this author in PubMed Google Scholar
Marion V. Guerin
View author publications
You can also search for this author in PubMed Google Scholar
Zacarias Garcia
View author publications
You can also search for this author in PubMed Google Scholar
Ruby Alonso
View author publications
You can also search for this author in PubMed Google Scholar
Fabrice Lemaître
View author publications
You can also search for this author in PubMed Google Scholar
Alexander Beer
View author publications
You can also search for this author in PubMed Google Scholar
Béatrice Corre
View author publications
You can also search for this author in PubMed Google Scholar
Laurie Menger
View author publications
You can also search for this author in PubMed Google Scholar
Capucine L. Grandjean
View author publications
You can also search for this author in PubMed Google Scholar
Florence Morin
View author publications
You can also search for this author in PubMed Google Scholar
Catherine Thieblemont
View author publications
You can also search for this author in PubMed Google Scholar
Sophie Caillat-Zucman
View author publications
You can also search for this author in PubMed Google Scholar
Philippe Bousso
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

M.B., M.C., M.V.G., Z.G., R.A., F.L., A.B., B.C. and C.L.G. conducted the experiments. A.C., F.M., C.T. and S.C.Z. conducted the clinical study. M.B. and P.B. designed the experiments. M.B. and P.B. analyzed the data and wrote the paper.

Corresponding author

Correspondence to Philippe Bousso.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Cancer thanks Gang Zhou and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 In vitro and ex vivo phenotyping of CAR T cells.

(a) CD4 and CD8 surface expression by CAR4 and CAR8 T cells (representative of n = 6 independent experiments). (b) CAR expression by WT and IFN-γ^−/− CD4⁺ T cells (representative of n = 8 independent experiments). CTRL4, untransduced control CD4⁺ T cells. (c) Representative FACS plot (left) and bar graphs (right) showing the percentage of effector/effector memory (CD44⁺ CD62L⁻), central memory (CD44⁺ CD62L⁺) and naive T cells (CD44⁻ CD62L⁺) in WT and IFN-γ^−/− CAR4 T cells (pooled from n = 3 independent experiments). Two-way ANOVA and Sidak’s multiple comparisons were used for statistical analysis. (d) Percentage of TIGIT, PD-1, LAG-3 and Tim-3 positive cells in WT and IFN-γ^−/− CAR4 T cells and their untransduced counterparts (CTRL4) after co-culture (or not) with pro-B-DEVD tumors at 1:1 effector-to-target ratio for 24 hours. Each dot represents one technical replicate (n = 1 experiment). (e, f) Ex vivo analysis of CAR4 T cells recovered from the bone marrow of pro-B-cell tumor-bearing mice 3 days after the treatment with WT or IFN-γ^−/− CAR4 T cells (10 × 10⁶). (e) Representative histograms (left) and bar graphs (right) showing the percentage of CD62L expressing cells in WT and IFN-γ^−/− CAR4 T cells. Each dot represents one mouse (n = 4 mice per group). Two-tailed Mann-Whitney U-test was used for statistical analysis. (f) Percentage of TIGIT, PD-1, LAG-3 and Tim-3 positive cells in WT and IFN-γ^−/− CAR4 T cells recovered from the bone marrow 3 days after their transfer. Each dot represents one mouse (n = 4 mice per group). Two-way ANOVA and Sidak’s multiple comparisons were used for statistical analysis. Data are expressed as mean ± SEM. *P<0.05; ns, not significant.

Source data

Extended Data Fig. 2 Gating strategies for flow cytometry identification of pro-B-cell tumors.

(a) Gating strategy for identifying pro-B-cell tumors expressing the FRET-based caspase 3 reporter (named DEVD) and tumor apoptosis in the bone marrow of tumor-bearing mice. CFP and YFP are linked by the target peptide DEVD, which is cleaved upon caspase 3 activation, resulting in loss of FRET in apoptotic cells. (b) Gating strategy for identifying CD45.1⁺ IFN-γ-R1^+/+ and CD45.2⁺ IFN-γ-R1^−/− pro-B-cell tumors in the bone marrow of tumor-bearing mice. (c) Gating strategy for identifying CFP⁺, GFP⁺, YFP⁺ and mTom⁺ pro-B-cell tumors in the bone marrow of tumor-bearing mice.

Extended Data Fig. 3 Kinetics of tumor apoptotic events mediated by CAR4 T cells.

Pro-B-cell tumors were established by intravenous injection of 0.5 × 10⁶ pro-B-DEVD tumor cells in C57BL/6 mice after sublethal irradiation. Six days later, mice were injected intravenously with WT CAR4 T cells and subjected to intravital two-photon imaging of the bone marrow. Apoptotic events (detected by the genetically-encoded FRET-based reporter for caspase 3 activity) were classified as direct killing when a CAR T cell engaged the target cell before FRET loss detection. Indirect events corresponded to tumor cells undergoing FRET loss without any apparent interactions with a CAR T cell. (a) Kinetics of direct CAR4 T cell-mediated killing events. (b) Kinetics of indirect tumor apoptotic events. Each line (n = 21) represents an individual tumor cell undergoing apoptosis during the imaging period. Gray squares represent periods without contact, green squares represent periods during which tumor cells are contacting a CAR4 T cell and blue squares represent periods during which tumor cells appear apoptotic. Data are representative of n = 26 hours of movie analyzed, from n = 3 mice from n = 3 independent experiments.

Extended Data Fig. 4 Role of IFN-γ production for the activity of CAR4 and CAR8 T cells.

(a-f) In vitro quantification of CAR4 T cell cytotoxic activity. (a) Pro-B-DEVD tumors were co-cultured with WT CAR4 T cells at 1:1 effector-to-target ratio or left untreated for 24 hours. When indicated, TRAIL and FasL were neutralized using a blocking antibody. Tumor cell death was assessed using fixable viability dye (Zombie NIR). Each dot represents one technical replicate. Data are representative of n = 2 independent experiments. (b, c) Pro-B-DEVD tumors were co-cultured with WT, IFN-γ^−/− or Prf1^−/− CAR4 T cells at 1:1 effector-to-target ratio or left untreated for 24 hours. (b) Tumor cell apoptosis was assessed using the FRET-based caspase 3 reporter. (c) Tumor cell death was assessed using fixable viability dye (Zombie NIR) and normalized to untreated tumor cells. (b–c) Each dot represents one technical replicate from n = 2 independent experiments for Prf1^−/− CAR4 T cells and n = 3 independent experiments for WT and IFN-γ^−/− CAR4 T cells. One-way ANOVA and Holm-Sidak’s multiple comparisons were used for statistical analysis. (d) Representative histograms of IFN-γ-R1 expression by WT (white) and CRISPR/Cas9 edited pro-B-cell tumors (black). (e) Functional validation of CRISPR/Cas9-mediated deletion of IFN-γ-R1 on pro-B-cell tumors. Pro-B-cell tumors were incubated with the indicated IFN-γ concentrations in vitro for 24 hours. H2-K^b surface expression analyzed by flow cytometry and expressed as a fold change relative to untreated cells. Each dot represents the mean of 3 technical replicates (n = 1 experiment). gMFI, geometric mean fluorescence intensity. (f) IFN-γ-R1^−/− pro-B-cell tumors were co-cultured with WT or IFN-γ^−/− CAR4 T cells at 1:1 effector-to-target ratio. Tumor cell death was assessed using fixable viability dye (Zombie NIR) and normalized to untreated tumor cells. Each dot represents one technical replicate (n = 1 experiment). (g) In vivo experimental setup. Pro-B-cell tumors were established by intravenous injection of 0.5 × 10⁶ of pro-B cells expressing the FRET-based caspase 3 reporter in IFN-γ^−/− mice after sublethal irradiation. Six days later, mice were injected intravenously with WT or IFN-γ^−/− CAR4 T cells. Three days after CAR T cell transfer, bone marrow cells were processed using flow cytometry. (h, i) CAR4 T cell-derived IFN-γ increases H2-K^b and PD-L1 levels in tumor and tumor-infiltrating immune cells. Surface expression of H2-K^b (left) and PD-L1 (right) was assessed on CD11b⁺ myeloid cells (H) and tumor cells (I). gMFI, geometric mean fluorescence intensity. Each dot represents one mouse (n = 4 mice per group from n = 1 experiment). One-way ANOVA, Tukey’s and Holm-Sidak’s multiple comparisons were used for statistical analysis. (j) Percentage of tumor cells recovered from the bone marrow. Each dot represents one mouse (n = 4 mice per group from n = 1 experiment). One-way ANOVA and Holm-Sidak’s multiple comparisons were used for statistical analysis. (k) In vitro quantification of CAR8 T cell cytotoxic activity. Pro-B-DEVD tumors were co-cultured with WT, IFN-γ^−/− or Prf1^−/− CAR8 T cells or untransduced control CD8⁺ T cells (CTRL8) at 1:1 effector-to-target ratio for 24 hours. Tumor cell death was assessed using fixable viability dye (Zombie NIR). Each dot represents one technical replicate (n = 1 experiment). (l) Pro-B-cell tumors were established by intravenous injection of 0.5 × 10⁶ pro-B-DEVD cells in C57BL/6 mice after sublethal irradiation. Six days later, mice were injected intravenously with WT or IFN-γ^−/− CAR8 T cells. (m) Percentage of tumor cells recovered from the bone marrow 3 days after the transfer of CAR8 T cells. Each dot represents one mouse (n = 11 untreated and n = 10 WT CAR8 T cell-treated mice from n = 3 independent experiments, n = 7 IFN-γ^−/− CAR8 T cell-treated mice from n = 2 independent experiments). One-way ANOVA and Tukey’s multiple comparisons were used for statistical analysis. Data are expressed as mean ± SEM. ***P<0.001; **P<0.01; *P<0.05; ns, not significant.

Source data

Extended Data Fig. 5 CAR4 T cells induce upregulation of ICAM-1 and PD-L1 molecules on both immune and tumor cells in the tumor microenvironment.

Pro-B-cell tumors were established by intravenous injection of 0.5 × 10⁶ pro-B-DEVD cells in C57BL/6 mice after sublethal irradiation. Six days later, mice were injected intravenously with WT or IFN-γ^−/− CAR4 T cells (5–10 × 10⁶). (a–b) CAR4 T cell-derived IFN-γ induces ICAM-1 and PD-L1 upregulation in both tumor and tumor-infiltrating immune cells. Bone marrow cells were analyzed using flow cytometry 3 days after CAR T cell transfer. Surface expression of ICAM-1 and PD-L1 was assessed on CD11b⁺ myeloid (A) and tumor cells (B). gMFI, geometric mean fluorescence intensity. Each dot represents one mouse (n = 10 untreated and n = 11 WT CAR4 T cell-treated mice from n = 3 independent experiments, n = 8 IFN-γ^−/− CAR4 T cell-treated mice from n = 2 independent experiments). One-way ANOVA and Tukey’s multiple comparisons were used for statistical analysis. Data are expressed as mean ± SEM. ***P<0.001; **P<0.01; *P<0.05; ns, not significant.

Source data

Extended Data Fig. 6 IFN-γ induces caspase 3 activation in pro-B cell tumors.

(a, b) Pro-B cell tumors were incubated with IFN-γ (0.5 or 50 ng.mL⁻¹) for 24 hours or left untreated. (a) Representative FACS plot and (B) bar graphs of cell death assessed using fixable viability dye (eFluor 780, eBioscience) and intracellular staining of activated caspase 3. Each dot represents one technical replicate (n = 1 experiment).

Source data

Extended Data Fig. 7 IFN-γ-R1 expression in the various B cell tumors.

(a–b) Validation of IFN-γ-R1^−/− pro-B cell tumors. (a) Impact of IFN-γ-induced cell death on IFN-γ-R1^+/+ and IFN-γ-R1^−/− pro-B cell tumors in vitro. Pro-B cell tumors were incubated with the indicated IFN-γ concentrations in vitro for 24 hours. Cell death was then assessed using fixable viability dye (Zombie NIR) and expressed as a fold change relative to untreated cells. (b) Pro-B cell tumors were incubated with the indicated IFN-γ concentrations in vitro for 24 hours. H2-K^b (left) and PD-L1 (right) surface expression was then analyzed by flow cytometry and expressed as a fold change relative to untreated cells. gMFI, geometric mean fluorescence intensity. (a, b) Data are pooled from n = 4 independent experiments. Two-way ANOVA and Sidak’s multiple comparisons were used for statistical analysis. (c) IFN-γ-R1 surface expression on Eµ-myc and pro-B cell tumors. Empty histograms represent the unstained control. (d) Eµ-myc and pro-B cell tumors respond to similar IFN-γ concentrations to upregulate PD-L1. Eµ-myc and pro-B cell tumors were incubated with the indicated IFN-γ concentrations in vitro for 24 hours. PD-L1 surface expression was then analyzed by flow cytometry. Data are pooled from n = 3 (Eµ-myc) and n = 5 (pro-B) independent experiments. gMFI, geometric mean fluorescence intensity. Two-way ANOVA and Sidak’s multiple comparisons were used for statistical analysis. (e) IFN-γ-R1 surface expression on GFP⁺, YFP⁺, CFP⁺ and mTom⁺ pro-B cell tumors. Note that the resistant CFP⁺ pro-B tumor cell line expressed similar levels of IFN-γ-R1 than the sensitive YFP⁺ pro-B tumor cell line. Empty histograms represent the unstained control. Data are expressed as mean ± SEM. ***P<0.001; **P<0.01; ns, not significant.

Source data

Extended Data Fig. 8 Mouse and human CAR4 T cells induce distant tumor killing in an IFN-γ-dependent manner.

(a) Experimental setup. Pro-B tumors were co-cultured with WT or IFN-γ^−/− CAR4 T cells (at an effector-to-target (E:T) ratio 5:1) in the upper chamber of a transwell. Pro-B tumors (expressing the caspase 3 reporter) were added to the lower chamber. When indicated, IFN-γ was neutralized using a blocking antibody. 24 hours later, pro-B tumors located in the lower chamber were analyzed by flow cytometry. (b, c) Dot plots showing that CAR4 T cell-derived IFN-γ diffuses to induce the up-regulation of H2-K^b (B) and PD-L1 (C) levels on tumor cells. gMFI, geometric mean fluorescence intensity. (d–e) Dot plots showing that CAR4 T cell-derived IFN-γ induces distant tumor cell killing. (d) Tumor cell apoptosis was assessed using the FRET-based caspase 3 reporter. (e) Tumor cell death was assessed using fixable viability dye (Zombie NIR). (b–e) Each dot represents one technical replicate (n = 1 experiment). (f) Representative histogram of human CD19 expression by retrovirally transduced OVCAR3 tumors. (g) In vitro quantification of human CAR4 T cell cytotoxic activity. Antigen-negative (CD19⁻) OVCAR3 or antigen-positive (CD19⁺) OVCAR3 tumors were co-cultured with human anti-CD19 CAR4 T cells at 1:1 effector-to-target ratio or left untreated for 48 hours. When indicated, IFN-γ and IFN-γ-R1 were neutralized using blocking antibodies. Tumor cell death was assessed using fixable viability dye (Zombie NIR). Each dot represents one technical replicate (n = 1 experiment). (h) Experimental setup. CD19-expressing OVCAR3 cells were co-cultured with human CAR4 T cells (at an effector-to-target (E:T) ratio 5:1) in the upper chamber of a transwell. CD19-expressing OVCAR3 tumors were added to the lower chamber. When indicated, IFN-γ and IFN-γ-R1 were neutralized using blocking antibodies. 48 hours later, CD19-expressing OVCAR3 tumors located in the lower chamber were analyzed by flow cytometry. (i) Dot plots showing that CAR4 T cell-derived IFN-γ diffuses to induce the up-regulation of HLA molecules (left) and PD-L1 (right) levels on tumor cells. gMFI, geometric mean fluorescence intensity. (j) Dot plots showing that CAR4 T cell-derived IFN-γ induces distant tumor cell death as assessed using fixable viability dye (Zombie NIR). (i, j) Each dot represents one technical replicate. Similar results were obtained in n = 2 independent experiments.

Source data

Extended Data Fig. 9 Murine and human CAR4 T cell-derived IFN-γ promotes the bystander killing of CD19⁻ target cells.

(a) Representative histogram of CD19 expression by antigen-positive (black) and CRISPR-edited antigen-negative (white) pro-B cell tumors. (b) Experimental setup. Antigen-negative (CD19⁻) pro-B tumors were co-cultured with antigen-positive (CD19⁺) pro-B tumors and WT or IFN-γ^−/− CAR4 T cells. When indicated, IFN-γ was neutralized using a blocking antibody. 48 hours later, apoptosis in CD19⁻ pro-B tumors (expressing the caspase 3 reporter) was analyzed by flow cytometry. (c, d) Representative FACS plots (C) and dot plots (D) showing that CAR4 T cell-derived IFN-γ produced upon recognition of CD19⁺ pro-B tumors contributes to the apoptosis of CD19⁻ pro-B tumors. Each dot represents one technical replicate (n = 1 experiment). CFP, Cyan Fluorescent Protein. (e) Experimental setup. Antigen-negative (CD19⁻) OVCAR3 tumors were co-cultured with antigen-positive (CD19⁺) OVCAR3 tumors and human anti-CD19 CAR4 T cells. When indicated, IFN-γ and IFN-γ-R1 were neutralized using blocking antibodies. 48 hours later, cell death in OVCAR3 tumors was analyzed by flow cytometry using fixable viability dye (Zombie NIR). (f) Dot plots showing that human CAR4 T cell-derived IFN-γ produced upon recognition of CD19⁺ OVCAR3 tumors contributes to the killing of antigen-negative OVCAR3 tumors. Each dot represents one technical replicate (n = 1 experiment). (g) In vivo experimental set-up. Pro-B cell tumors were established by intravenous injection of 0.5 × 10⁶ of pro-B cells expressing the FRET-based caspase 3 reporter in C57BL/6 mice after sublethal irradiation. Six days later, mice were injected intravenously with WT or IFN-γ^−/− CAR4 T cells or left untreated. Seven days after CAR T cell transfer, blood cells were processed using flow cytometry. (h) Percentage of antigen-positive (CD19⁺) and emerging antigen-negative (CD19⁻) pro-B tumors tumor cells recovered from the blood (n = 7 untreated, n = 8 WT CAR4 T cell-treated and n = 8 IFN-γ^−/− CAR4 T cell-treated mice from 1 experiment). Statistics for antigen-negative (CD19⁻) pro-B tumors are shown. Two-way ANOVA and Tukey’s multiple comparisons were used for statistical analysis. Data are expressed as mean ± SEM. *P<0.05; ns, not significant.

Source data

Extended Data Fig. 10 IFN-γ contributes to CAR4 T cell-mediated killing of some but not all solid tumors.

(a, b) Impact of IFN-γ on two distinct solid tumors, colon adenocarcinoma MC38 cells and melanoma B16.F10 cells. MC38 and B16.F10 tumors were incubated with the indicated IFN-γ concentrations in vitro for 24 hours. (a) Cell death was assessed using fixable viability dye (Zombie NIR) and expressed as a fold change relative to untreated cells. (b) IFN-γ induces phenotypic changes in both MC38 and B16.F10 tumors in vitro. H2-K^b (left) and PD-L1 (right) surface expression was then analyzed by flow cytometry. gMFI, geometric mean fluorescence intensity. (a, b) Each dot represents the mean of 3 technical replicates from n = 2 independent experiments. Two-way ANOVA and Sidak’s multiple comparisons were used for statistical analysis. (c) CD19-expressing MC38 and CD19-expressing B16.F10 tumors were co-cultured with WT or IFN-γ^−/− CAR4 T cells at 1:1 effector-to-target ratio or left untreated for 24 hours. When indicated, IFN-γ was neutralized using a blocking antibody. Tumor cell death was assessed using fixable viability dye (Zombie NIR). Each dot represents one technical replicate (n = 1 experiment). (d-e) B16-CD19 tumors were established by subcutaneous injection of 0.5 × 10⁶ B16-CD19 cells in the flank of C57BL/6 mice after sublethal irradiation. Ten days later, mice were injected intravenously with WT or IFN-γ^−/− CAR4 T cells (10 × 10⁶) or left untreated (n = 7 untreated mice, n = 7 WT CAR4 T cell-treated mice and n = 8 IFN-γ^−/− CAR4 T cell-treated mice from 1 experiment). (d) Tumor growth was monitored every 2–3 days. Two-way ANOVA and Tukey’s multiple comparisons were used for statistical analysis. (e) WT CAR4 but not IFN-γ^−/− CAR4 T cell therapy prolonged mouse survival. Log-rank test was used for statistical analysis. Data are expressed as mean ± SEM. ***P<0.001; **P<0.01; *P<0.05; ns, not significant.

Source data

Supplementary information

Reporting Summary

Supplementary Video 1

Examples of direct and indirect tumor killing during CAR4 T-cell therapy. C57BL/6 mice were sublethally irradiated and injected with Pro-B-DEVD cell tumors 6 d before treatment with GFP-expressing CAR4 T cells. After 2–3 d, intravital imaging of the bone marrow was performed. The video shows one example of a tumor cell undergoing apoptosis following a direct cellular contact with a CAR4 T cell (direct killing events) and one example of tumor cells undergoing apoptosis without apparent contact with CAR4 T cells (indirect killing events). The white circle highlights the tumor cell undergoing apoptosis following a cellular contact with a CAR4 T cell. The red circles highlight tumor cells undergoing apoptosis without apparent contact with CAR4 T cells. CAR4 T cells are shown in green, live tumor cells in white and apoptotic tumor cells in blue. Scale bars, 10 µm.

Supplementary Video 2

WT CAR4 T cells eliminate tumors using both contact-dependent and independent mechanisms. C57BL/6 mice were sublethally irradiated and injected with Pro-B-DEVD cell tumors 6 d before treatment with GFP-expressing WT CAR4 T cells. After 3 d, intravital imaging of the bone marrow was performed. The white circles highlight tumor cells undergoing apoptosis following a direct cellular contact with a WT CAR4 T cell (direct killing events). The red circles highlight tumor cells undergoing apoptosis without apparent contact with WT CAR4 T cells (indirect killing events). CAR4 T cells are shown in green, live tumor cells in white and apoptotic tumor cells in blue. Scale bars, 30 µm. Total duration 1 h 15 min.

Supplementary Video 3

IFN-γ^−/− CAR4 T cells primarily induce direct, contact-dependent tumor killing. C57BL/6 mice were sublethally irradiated and injected with Pro-B-DEVD cell tumors 6 d before treatment with GFP-expressing IFN-γ^−/− CAR4 T cells. After 3 d, intravital imaging of the bone marrow was performed. The white circles highlight tumor cells undergoing apoptosis following a direct cellular contact with an IFN-γ^−/− CAR4 T cell (direct killing events). The red circle highlights a tumor cell undergoing apoptosis without apparent contact with IFN-γ^−/− CAR4 T cells (indirect killing events). CAR4 T cells are shown in green, live tumor cells in white and apoptotic tumor cells in blue. Scale bars, 30 µm. Total duration 1 h 6 min.

Supplementary Video 4

Prf1^−/− CAR4 T cells primarily induce indirect tumor cell killing. C57BL/6 mice were sublethally irradiated and injected with Pro-B-DEVD cell tumors 6 d before treatment with GFP-expressing Prf1^−/− CAR4 T cells. After 2 d, intravital imaging of the bone marrow was performed. The white circle highlights a tumor cell undergoing apoptosis following a direct cellular contact with a Prf1^−/− CAR4 T cell (direct killing events). The red circles highlight tumor cells undergoing apoptosis without apparent contact with Prf1^−/− CAR4 T cells (indirect killing events). CAR4 T cells are shown in green, live tumor cells in white and apoptotic tumor cells in blue. Scale bars, 30 µm. Total duration 59 min.

Supplementary Video 5

Indirect tumor killing events are not the result of perforin-dependent elimination by host cytotoxic effectors. Prf1^−/− mice were sublethally irradiated and injected with Pro-B-DEVD cell tumors 6 d before treatment with GFP-expressing WT CAR4 T cells. After 2 d, intravital imaging of the bone marrow was performed. The white circle highlights a tumor cell undergoing apoptosis following a direct cellular contact with a WT CAR4 T cell (direct killing events). The red circles highlight tumor cells undergoing apoptosis without apparent contact with WT CAR4 T cells (indirect killing events). CAR4 T cells are shown in green, live tumor cells in white and apoptotic tumor cells in blue. Scale bars, 30 µm. Total duration 59 min.

Source data

Source Data Fig. 1

Statistical Source Data for Fig. 1.

Source Data Fig. 2

Statistical Source Data for Fig. 2.

Source Data Fig. 3

Statistical Source Data for Fig. 3.

Source Data Fig. 4

Statistical Source Data for Fig. 4.

Source Data Fig. 5

Statistical Source Data for Fig. 5.

Source Data Fig. 6

Statistical Source Data for Fig. 6.

Source Data Fig. 7

Statistical Source Data for Fig. 7.

Source Data Extended Data Fig. 1

Statistical Source Data for Extended Data Fig. 1.

Source Data Extended Data Fig. 4

Statistical Source Data for Extended Data Fig. 4.

Source Data Extended Data Fig. 5

Statistical Source Data for Extended Data Fig. 5.

Source Data Extended Data Fig. 6

Statistical Source Data for Extended Data Fig. 6.

Source Data Extended Data Fig. 7

Statistical Source Data for Extended Data Fig. 7.

Source Data Extended Data Fig. 8

Statistical Source Data for Extended Data Fig. 8.

Source Data Extended Data Fig. 9

Statistical Source Data for Extended Data Fig. 9.

Source Data Extended Data Fig./ 10

Statistical Source Data for Extended Data Fig. 10.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Boulch, M., Cazaux, M., Cuffel, A. et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4⁺ CAR T-cell antitumor activity. Nat Cancer 4, 968–983 (2023). https://doi.org/10.1038/s43018-023-00570-7

Download citation

Received: 16 September 2022
Accepted: 27 April 2023
Published: 29 May 2023
Issue Date: July 2023
DOI: https://doi.org/10.1038/s43018-023-00570-7

This article is cited by

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion
- Leilei Zhao
- Yudi Wang
- Yucui Dong
Cancer Cell International (2024)
HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
- Jianting Long
- Xihe Chen
- Yanyan Han
Nature Communications (2024)
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
- Cristina Aparicio
- Carlos Acebal
- Margarita González-Vallinas
Experimental Hematology & Oncology (2023)
CD4+ CAR T cells — more than helpers
- M. Eric Kohler
- Terry J. Fry
Nature Cancer (2023)
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
- Ali Ghasemi
- Amaia Martinez-Usatorre
- Michele De Palma
Nature Cancer (2023)

Subjects

Abstract

Similar content being viewed by others

Main

Results

CD4+ CAR T cells exhibit tumor-dependent antitumor activity

CAR4 T cells rely on IFN-γ to control pro-B-cell tumors

Elimination of tumors by CAR4 T cells without cell contact

CAR4 T-cell-derived IFN-γ is sensed by immune and tumor cells

CAR4 T-cell-derived IFN-γ promotes tumor cell apoptosis

CAR4 T cells selectively eliminate IFN-γ-sensitive tumors

IFN-γ predicts survival in patients with high CAR4 T cells

Discussion

Methods

Ethics statement

Mice and cell lines

CAR T-cell generation and adoptive transfer

Generation of IFN-γ-R1−/− pro-B cells

IFN-γ treatments

Transwell assay

Multiplex assay for cytokine quantification

Flow cytometry and antibodies

In vitro imaging

Intravital two-photon imaging of the bone marrow

Image analysis

Patients and immune monitoring

Statistics and reproducibility

Reporting summary

Data availability

References

Acknowledgements

Author information

Authors and Affiliations

Contributions

Corresponding author

Ethics declarations

Competing interests

Peer review

Peer review information

Additional information

Extended data

Supplementary information

Source data

Rights and permissions

About this article

Cite this article

Share this article

This article is cited by

Search

Quick links

CD4⁺ CAR T cells exhibit tumor-dependent antitumor activity

Generation of IFN-γ-R1^−/− pro-B cells